These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1046914)

  • 1. Do's and don'ts for the patient on levodopa therapy.
    Langan RJ; Cotzias GC
    Am J Nurs; 1976 Jun; 76(6):917-8. PubMed ID: 1046914
    [No Abstract]   [Full Text] [Related]  

  • 2. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
    Barbeau A
    Can Med Assoc J; 1975 Jun; 112(12):1379-80. PubMed ID: 1139474
    [No Abstract]   [Full Text] [Related]  

  • 4. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent advances in the treatment of Parkinson's disease.
    Martocci RJ
    J Am Osteopath Assoc; 1975 Apr; 74(8):730-41. PubMed ID: 1092751
    [No Abstract]   [Full Text] [Related]  

  • 6. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 7. [Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase].
    Nurzia A
    Clin Ter; 1975 Feb; 72(3):289-95. PubMed ID: 1132216
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug therapy of parkinsonism.
    Bianchine JR
    N Engl J Med; 1976 Oct; 295(15):814-8. PubMed ID: 958277
    [No Abstract]   [Full Text] [Related]  

  • 9. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 10. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
    Jankovic J
    Ann Neurol; 1981 Jul; 10(1):64-5. PubMed ID: 7271235
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 13. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
    Dessibourg CA; Gachoud JP
    Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
    Sweet RD; McDowell FH
    Adv Neurol; 1974; 5():331-8. PubMed ID: 4440581
    [No Abstract]   [Full Text] [Related]  

  • 16. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diet therapy helps this drug work better.
    Cerrato PL
    RN; 1991 Feb; 54(2):71-2, 74. PubMed ID: 1994474
    [No Abstract]   [Full Text] [Related]  

  • 18. [New directions in contemporary pharmacotherapy of parkinsonism (review)].
    Kurako IuL; Volianskiĭ VE
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1401-6. PubMed ID: 6150591
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
    Agid Y; Quinn N; Lhermitte F
    Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.